Observing Wilms Tumors in Children at Shefa Al-Orman Hospital
Study of Wilms Tumors Among Patients of Shefa Al-Orman Children Cancer Hospital
This study looks at how common Wilms tumors are in children being treated at Shefa Al-Orman Hospital and checks how well the treatments are working and any side effects they might have.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | N/A to 18 Years |
| Sex | All |
| Sponsor | South Egypt Cancer Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Luxor) |
| Trial ID | NCT06288802 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence of Wilms tumors among pediatric cancers at Shefa Al-Orman Children Cancer Hospital from June 2020 to June 2024. It will evaluate the outcomes of patients treated according to the SIOP Umbrella protocol and analyze treatment-related complications using the CTCAE Version 5.0 criteria. Data will be collected through patient history, physical examinations, and laboratory studies to provide a comprehensive understanding of Wilms tumors in this population.
Who should consider this trial
Good fit: Ideal candidates include children and young adolescents under 18 years old who are admitted and treated at Shefa Al-Orman Children Cancer Hospital during the study period.
Not a fit: Patients older than 18 years, those who die before starting chemotherapy, or those with non-Wilms renal tumors will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of Wilms tumors and improve treatment protocols for affected children.
How similar studies have performed: While similar studies have been conducted, this specific observational approach focusing on Wilms tumors in this region is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children and young adolescene younger than 18 years of age admitted and treated at Shefa Al-orman Children Cancer Hospital during the study period Exclusion Criteria: * Patients aged older than 18 years old, died early at presentation before starting chemotherapy, patients with non-Wilms renal tumors, relapsed renal tumors.
Where this trial is running
Luxor
- Shefa Al-orman Children Cancer Hospital — Luxor, Egypt (Recruiting)
Study contacts
- Principal investigator: Mahmoud Elzembely, MD — South Egypt Cancer Institute
- Study coordinator: Mahmoud Elzembely, MD
- Email: elzimbily@aun.edu.eg
- Phone: +201146703107
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.